Molecules

PSMA-11

Target PSMAClass Small molecule (urea, HBED-CC chelator)Other names gozetotide, Glu-urea-Lys(Ahx)-HBED-CC

18ongoing trials
1radiolabelled forms
1approved products
1,345publications (PubMed)

Structure

Structure from the cited PubChem record (unlabelled ligand, or the labelled form when PubChem only describes that one). Conformer: RDKit (computed conformer, indicative). Rotate with the mouse or a finger.

Properties (PubChem)

Molecular formula
C44H62N6O17
Molar mass (g/mol)
947
Exact mass (Da)
946.4171
XLogP
-3.9
H-bond donors
12
H-bond acceptors
19
Rotatable bonds
35
Heavy atoms
67
InChIKey
QJUIUFGOTBRHKP-LQJZCPKCSA-N
PubChem record
CID 60143283 ↗
IUPAC name
(2S)-2-[[(1S)-1-carboxy-5-[6-[3-[3-[[2-[[5-(2-carboxyethyl)-2-hydroxyphenyl]methyl-(carboxymethyl)amino]ethyl-(carboxymethyl)amino]methyl]-4-hydroxyphenyl]propanoylamino]hexanoylamino]pentyl]carbamoylamino]pentanedioic acid
SMILES
C1=CC(=C(C=C1CCC(=O)NCCCCCC(=O)NCCCC[C@@H](C(=O)O)NC(=O)N[C@@H](CCC(=O)O)C(=O)O)CN(CCN(CC2=C(C=CC(=C2)CCC(=O)O)O)CC(=O)O)CC(=O)O)O

Radiolabelled forms

FormUseMolar mass (labelled form)Ongoing trialsMost advanced phaseApproval
[⁶⁸Ga]Ga-PSMA-11 Syntheses and QC ↗Imaging1,011.918Phase 3PSMA-11 (Locametz, Illuccix, Gozellix…) US EU FR JP

Ongoing trials · 18Open in the radar →

Atlas trials whose studied drug or title names this vector, with this radionuclide.

TrialPhaseStatusSponsorCountries
[68Ga]Ga-PSMA-112023-504917-54-00 · Prostate – localised / recurrencePhase 3RecruitingKarolinska University Hospital1
PSMA SRT · [68Ga]Ga-PSMA-11NCT03582774 · Prostate – otherPhase 3Active, not recruitingJonsson Comprehensive Cancer Center1
BiPASS · [68Ga]Ga-PSMA-11NCT07052214 · Prostate – otherPhase 3Active, not recruitingTelix Pharmaceuticals (Innovations) Pty Limited2
[68Ga]Ga-PSMA-112023-506032-33-00 · Prostate – localised / recurrencePhase 3Not yet recruitingUniversitaetsklinikum Essen AöR1
[68Ga]Ga-PSMA-112024-518171-59-00 · Prostate – otherPhase 3RecruitingCanisius Wilhelmina Ziekenhuis1
[68Ga]Ga-PSMA-11NCT07209878 · Prostate – otherPhase 3RecruitingFirst Affiliated Hospital of Fujian Medical University1
[68Ga]Ga-PSMA-112024-514181-39-00 · KidneyPhase 3RecruitingStichting Radboud universitair medisch centrum1
[68Ga]Ga-PSMA-112024-517098-26-00 · KidneyPhase 2RecruitingCliniques Universitaires Saint-Luc1
[68Ga]Ga-PSMA-11NCT04777071 · Prostate – mCRPCPhase 2Active, not recruitingUniversity of Washington1
[68Ga]Ga-PSMA-11NCT06444412 · Brain (glioma, medulloblastoma…)Phase 2RecruitingMayo Clinic1
[68Ga]Ga-PSMA-11NCT05160597 · Prostate – otherPhase 1Active, not recruitingJonsson Comprehensive Cancer Center1
[68Ga]Ga-PSMA-11NCT06209567 · Brain (glioma, medulloblastoma…)Phase 1Active, not recruitingMemorial Sloan Kettering Cancer Center1
[68Ga]Ga-PSMA-11NCT04147494 · Prostate – otherPhase 1Active, not recruitingJonsson Comprehensive Cancer Center1
[68Ga]Ga-PSMA-11NCT06696326 · Prostate – otherNo phaseRecruitingThe First Affiliated Hospital of Xiamen University1
Other PSMA ligandNCT05324332 · Prostate – otherNo phaseRecruitingPeking Union Medical College Hospital1
HIMIKO · [68Ga]Ga-PSMA-11NCT06999837 · Liver (HCC)No phaseRecruitingNantes University Hospital1
INTROSPECT · [68Ga]Ga-PSMA-11NCT07829068 · Prostate – localised / recurrenceNo phaseActive, not recruitingUniversity Hospital, Geneva1
[68Ga]Ga-PSMA-11NCT07365397 · Prostate – otherNo phaseNot yet recruitingShanghai Zhongshan Hospital0
Other trials listing it among the interventions (comparator, associated scan) · 1
[18F]FDGNCT06335914 · Prostate – otherNo phaseRecruitingUniversity Health Network, Toronto1

Published results · 5

2026-09PSMA PET-guided robotic biopsy · positiveIn 217 randomized men with a PI-RADS 4 or 5 lesion, robotic biopsy guided by PSMA PET detects cancer in 97% of patients vs 81% for ultrasound-guided biopsy with cognitive MRI fusion. Fewer complications (11% vs 51%), less pain and fewer cores.J Nucl Med ↗
2026-07PSMA-11 with cyclotron gallium · earlyIn Japan, in 9 men, PSMA-11 labeled with cyclotron-produced gallium-68 (automated module, about 2.8 GBq per synthesis, purity above 99%) is well tolerated, with expected dosimetry and all primary lesions detected.Ann Nucl Med ↗
2026-06PRIMARY2 · positiveIn 660 men at high clinical risk but with a non-suspicious or equivocal MRI (PI-RADS 2-3), first-line PSMA PET is non-inferior to systematic biopsy for detecting significant cancer (12% vs 16%) and avoids biopsy in 49% of patients. Comparable biopsy safety.Lancet Oncol ↗
2026-06PROSPET-BX · positiveIn 130 men with suspected cancer after at least one negative biopsy, the PSMA PET PRIMARY score is more accurate than MRI PI-RADS (92% vs 83%). The authors derive a predictive nomogram before repeat biopsy (AUC 0.90).Eur J Nucl Med Mol Imaging ↗
2026-06EMPIRE-2 · mixedIn 134 patients with recurrence after prostatectomy, randomized between the two tracers, PET changes the radiotherapy decision in 29% (fluciclovine) and 42% (PSMA) of cases, with no significant difference between tracers. Radiation fields change more often with fluciclovine.Radiology ↗

PublicationsAll publications in PubMed ↗

1,345 publications in PubMed for the query below; the most recent:

"PSMA-11"[tiab] OR gozetotide[tiab] OR "PSMA 11"[tiab]

  1. Dynamically visualizing the effects of rTMS on GCPII repair after ischemic stroke by [(68)Ga]Ga-PSMA-11 PET/CT Exp Neurol, 2027
  2. Near-complete Response of Bilateral Adrenal Metastases to 177Lu-PSMA Therapy in Castration-resistant Prostate Cancer on Posttherapeutic SPECT-CT Follow Up Clin Nucl Med, 2026
  3. A comparative assessment of [ 99m Tc] HYNIC-PSMA-11 scintigraphy in prostate cancer as a potential substitute for disease evaluation with [ 68 Ga] PSMA-11 PET/CT imaging Nucl Med Commun, 2026
  4. Intramedullary Spinal Cord Metastasis (SCM) From Prostate Carcinoma Detected on [ 68 Ga] Ga-PSMA-11 PET/CT Clin Nucl Med, 2026
  5. Multimodal Evaluation of [(225)Ac]Ac-PSMA-617 Therapy in mCRPC: PET Based Total Tumor Volume, PSA Kinetics, and Blood Biomarkers Int J Mol Sci, 2026
  6. A Head-to-Head Comparison of Detection Rate and Tumor Uptake of FAPI, PSMA, and FDG PET/CT in Newly Diagnosed High-risk Prostate Cancer Clin Nucl Med, 2026
  7. Not Every PSMA-Expressing Bone Lesion Is Prostate Cancer: Incidental Detection of Metastatic Differentiated Thyroid Carcinoma on Staging 68Ga-PSMA-11 PET/CT Clin Nucl Med, 2026
  8. Performance of(68)Ga-PSMA-11 PET/CT for Diagnosing Tumor Thrombus and Predicting Response to Pembrolizumab and Axitinib in Patients with Renal Cell Carcinoma: A Pilot, Retrospective Study Ann Surg Oncol, 2026

Sources: PubChem and PubMed (NCBI), ClinicalTrials.gov and CTIS registries, approvals recorded by the atlas. PubChem data as of 28 October 2026.

Cite this page

PSMA-11. Theranostic Atlas, LaRadiopharmacie.fr. Data as of 27 October 2026. https://theranosticatlas.com/molecule/psma-11/ (accessed [date]).

A monitoring tool with no regulatory value: check every item at its source.